[go: up one dir, main page]

TR200001736T2 - Dikkat noksanlığı rahatsızlığının tedavisi için yöntem ve terkipler. - Google Patents

Dikkat noksanlığı rahatsızlığının tedavisi için yöntem ve terkipler.

Info

Publication number
TR200001736T2
TR200001736T2 TR2000/01736T TR200001736T TR200001736T2 TR 200001736 T2 TR200001736 T2 TR 200001736T2 TR 2000/01736 T TR2000/01736 T TR 2000/01736T TR 200001736 T TR200001736 T TR 200001736T TR 200001736 T2 TR200001736 T2 TR 200001736T2
Authority
TR
Turkey
Prior art keywords
attention deficit
compositions
treatment
methods
deficit disorder
Prior art date
Application number
TR2000/01736T
Other languages
English (en)
Inventor
Mantelle Juan
A. Dixon Terese
Original Assignee
Noven Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26750154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200001736(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Pharmaceuticals, Inc. filed Critical Noven Pharmaceuticals, Inc.
Publication of TR200001736T2 publication Critical patent/TR200001736T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Bu bulus dikkat eksikligi rahatsizligi (ADD) ve dikkat eksikligi/hiperaktivite rahatsizliginin (ADHD) tedavisine iliskin bir yöntemle ve metilfenidatin, bu maddeye ihtiyaç duyan bir hastanin derisi veya mukozasi yoluyla iletimi için en az 10 saatlik bir zaman peryodu içerisinde sifir-düzey kinetigini önemli ölçüde korumaya yeterli miktarda bulundugu ve ihtiva ettigi asit fonksiyonel monomer orani agirlik bazinda yaklasik %5'ten fazla olmayan esnek, sonlu bir sistemde metilfenidatin topik olarak uygulanmasini saglayan bilesimlerle ilgilidir.
TR2000/01736T 1997-12-15 1998-12-14 Dikkat noksanlığı rahatsızlığının tedavisi için yöntem ve terkipler. TR200001736T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6951097P 1997-12-15 1997-12-15
US09/163,351 US6210705B1 (en) 1997-12-15 1998-09-30 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate

Publications (1)

Publication Number Publication Date
TR200001736T2 true TR200001736T2 (tr) 2001-01-22

Family

ID=26750154

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01736T TR200001736T2 (tr) 1997-12-15 1998-12-14 Dikkat noksanlığı rahatsızlığının tedavisi için yöntem ve terkipler.

Country Status (28)

Country Link
US (2) US6210705B1 (tr)
EP (2) EP1037615B1 (tr)
JP (3) JP4316800B2 (tr)
KR (1) KR100633348B1 (tr)
CN (1) CN1368876A (tr)
AR (1) AR014062A1 (tr)
AT (1) ATE260652T1 (tr)
AU (1) AU752027B2 (tr)
BR (1) BR9814282A (tr)
CA (1) CA2315237C (tr)
CZ (2) CZ305817B6 (tr)
DE (1) DE69822199T2 (tr)
DK (1) DK1037615T3 (tr)
ES (2) ES2452517T3 (tr)
HK (1) HK1049447A1 (tr)
HU (1) HU226615B1 (tr)
IL (1) IL136760A0 (tr)
LV (1) LV12558B (tr)
NO (1) NO329974B1 (tr)
NZ (1) NZ505689A (tr)
PE (1) PE20000120A1 (tr)
PL (1) PL195315B1 (tr)
PT (1) PT1037615E (tr)
RU (1) RU2233156C2 (tr)
SI (1) SI20360B (tr)
TR (1) TR200001736T2 (tr)
TW (2) TWI244396B (tr)
WO (1) WO1999030694A2 (tr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
CO5261532A1 (es) * 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
US7384959B2 (en) * 1999-12-17 2008-06-10 Celltech Pharma Europe Limited Treatment of convulsive states
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6905016B2 (en) * 2000-03-14 2005-06-14 Noven Pharmaceuticals, Inc. Packaging system for transdermal drug delivery systems
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US7988991B2 (en) * 2001-03-07 2011-08-02 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
FR2822049B1 (fr) * 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
CN101524339A (zh) * 2001-03-16 2009-09-09 阿尔扎公司 施用芬太尼的经皮贴剂
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
ME00114B (me) * 2003-10-28 2011-02-10 Noven Pharma Kompozicije i postupci za kontrolisanje gubitka i oslobađanja lijeka u transdermalnim sistemima oslobađanja lijeka
CA2595400C (en) * 2005-01-20 2017-01-17 Institute For Molecular Medicine, Inc. Methylphenidate derivatives and their use in the treatment of angiogenic diseases and conditions
US20060183773A1 (en) * 2005-01-20 2006-08-17 David Bar-Or Uses of methylphenidate derivatives
EP1962815B1 (de) * 2005-12-23 2010-08-11 Epinamics GmbH Verwendung filmbildender haarpflegepolymere aus der gruppe der polyurethane und diese polymere enthaltende pharmazeutische zubereitungen und pflaster
US9393218B2 (en) * 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
MX2008010934A (es) * 2006-02-27 2008-10-30 Noven Pharma Sistema terapeutico transdermico que contiene escopolamina.
US8568695B2 (en) * 2006-05-01 2013-10-29 Colgate-Palmolive Company Oral care composition with silicone composite
CA2678806C (en) * 2007-02-21 2017-05-16 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
MY154027A (en) * 2007-10-15 2015-04-30 Alza Corp Once-a-day replacement transdermal administration of fentanyl
FR2924350B1 (fr) * 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
ES2524696T3 (es) * 2007-12-31 2014-12-11 Acclarent, Inc. Vendaje del tejido de la mucosa y método de uso
FR2926466B1 (fr) * 2008-01-23 2010-11-12 Dbv Tech Procede de fabrication de patchs par electrospray
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
EP2942196B8 (en) * 2009-06-05 2018-01-10 Babcock & Wilcox MEGTEC, LLC Improved infrared float bar
EP2364695A1 (en) 2010-02-10 2011-09-14 Nitto Denko Corporation Methylphenidate patch preparation
US20110200663A1 (en) * 2010-02-12 2011-08-18 Nitto Denko Corporation Methylphenidate patch preparation
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
PT2688557T (pt) 2011-03-23 2017-11-23 Ironshore Pharmaceuticals & Dev Inc Métodos e composições para o tratamento de distúrbio de défice de atenção
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
CN107261148B (zh) * 2011-07-28 2021-07-13 凯姆制药公司 哌甲酯前药、其制备和使用方法
US9717697B2 (en) 2012-10-15 2017-08-01 Noven Pharmaceuticals, Inc. Compositions and methods for the transdermal delivery of methylphenidate
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014106014A1 (en) 2012-12-28 2014-07-03 Noven Pharmaceuticals, Inc Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
MX366230B (es) 2012-12-28 2019-07-03 Noven Pharma Composiciones multipolimericas para liberación transdermica de farmaco.
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2014159582A1 (en) 2013-03-14 2014-10-02 Noven Pharmaceuticals, Inc Amphetamine transdermal compositions with acrylic block copolymer
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
AR095260A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones de anfetaminas transdérmicas estables y métodos de fabricación
AU2014371437B2 (en) 2013-12-25 2020-01-30 Fujimoto Co., Ltd. Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
CN106511264A (zh) * 2016-11-15 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸哌甲酯口服溶液剂及其制备方法
HUE067004T2 (hu) 2016-12-11 2024-10-28 Zevra Therapeutics Inc Metilfenidát prodrogokat tartalmazó készítmények, eljárások azok elõállítására és felhasználására
EP3598982A1 (en) 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives
JP7600661B2 (ja) * 2020-12-11 2024-12-17 artience株式会社 貼付剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3910578A1 (de) * 1989-03-29 1990-10-04 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
WO1992021333A2 (en) * 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
ATE152630T1 (de) 1992-07-28 1997-05-15 Procter & Gamble Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält
CH691209A5 (de) 1993-09-06 2001-05-15 Scherrer Inst Paul Herstellungsverfahren für einen Polmerelektrolyten und elektrochemische Zelle mit diesem Polymerelektrolyten.
EP0689920B1 (de) 1994-06-29 1999-10-13 Hennecke GmbH Verfahren und Vorrichtung zum kontinuierlichen Herstellen von Schaumstoffblöcken oder Schaumstoffbahnen
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
AU2590697A (en) 1997-03-07 1998-09-22 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, s ystems and methods
GB9711032D0 (en) 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
EP1710506A2 (en) 1999-12-15 2006-10-11 Osaka Gas Co., Ltd. Burner Apparatus, Gas Turbine Engine and Cogeneration System

Also Published As

Publication number Publication date
KR100633348B1 (ko) 2006-10-16
BR9814282A (pt) 2000-10-03
RU2233156C2 (ru) 2004-07-27
EP1037615B1 (en) 2004-03-03
NZ505689A (en) 2003-01-31
ATE260652T1 (de) 2004-03-15
LV12558A (lv) 2000-11-20
CA2315237C (en) 2009-12-01
NO20003096D0 (no) 2000-06-15
LV12558B (en) 2001-03-20
AU752027B2 (en) 2002-09-05
CA2315237A1 (en) 1999-06-24
US6348211B1 (en) 2002-02-19
ES2219926T3 (es) 2004-12-01
EP2314288A1 (en) 2011-04-27
SI20360A (sl) 2001-04-30
NO20003096L (no) 2000-08-15
IL136760A0 (en) 2001-06-14
NO329974B1 (no) 2011-01-31
PE20000120A1 (es) 2000-02-19
EP2314288B1 (en) 2013-12-11
JP2002510600A (ja) 2002-04-09
WO1999030694A3 (en) 1999-08-19
CZ20002209A3 (cs) 2000-11-15
SI20360B (sl) 2008-06-30
AR014062A1 (es) 2001-01-31
PL341596A1 (en) 2001-04-23
DE69822199D1 (de) 2004-04-08
TWI242452B (en) 2005-11-01
CZ300535B6 (cs) 2009-06-10
EP1037615A2 (en) 2000-09-27
HK1049447A1 (zh) 2003-05-16
ES2452517T3 (es) 2014-04-01
CN1368876A (zh) 2002-09-11
WO1999030694A2 (en) 1999-06-24
DK1037615T3 (da) 2004-07-12
AU1824999A (en) 1999-07-05
JP2009073856A (ja) 2009-04-09
KR20010033114A (ko) 2001-04-25
JP2013056944A (ja) 2013-03-28
TWI244396B (en) 2005-12-01
CZ2009132A3 (cs) 2016-03-23
HK1156872A1 (en) 2012-06-22
HUP0004539A3 (en) 2006-06-28
PL195315B1 (pl) 2007-08-31
HU226615B1 (en) 2009-04-28
HUP0004539A2 (hu) 2001-06-28
CZ305817B6 (cs) 2016-03-23
TW200406231A (en) 2004-05-01
DE69822199T2 (de) 2005-02-17
US6210705B1 (en) 2001-04-03
JP4316800B2 (ja) 2009-08-19
PT1037615E (pt) 2004-07-30

Similar Documents

Publication Publication Date Title
TR200001736T2 (tr) Dikkat noksanlığı rahatsızlığının tedavisi için yöntem ve terkipler.
DK1039874T3 (da) Sammensætninger og metoder til behandling af alopecia
EE200000039A (et) MHC II klassi ligandi kasutamine, farmatseutiline kompositsioon, transfekteeritud kasvajarakud, transfekteeritud rakkude ja kasvajarakkude valmistamismeetod ning nende kasutamine
DE59209658D1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
ATE156517T1 (de) Antisens-oligonukleotide zur behandlung von krebs
DK1014954T3 (da) Transdermalt terapeutisk system
ATE59547T1 (de) Mittel zum reduzieren der ausbreitung des sebums.
EE03004B1 (et) Tselluloosi sisaldava teraviljaekstrakti valmistamise meetod
ATE335469T1 (de) Transdermales therapeutisches system (tts) tolterodin enthaltend
DE69618651D1 (de) Mittel zur behandlung von keratinmaterial, das mindestens ein silikon geproptes polymer und mindenstens ein verdickendes polymer oder copolymer von (meth) acrylamid oder einem (meth) acrylamidderivat enthalt, sowie dessen verwendungen
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
NO962655D0 (no) Deutrerte virkestoffer i transdermal applikasjon
BR0311963A (pt) Sistema de distribuição de droga de difusão controlada por matriz, método para produzir e para utilizar o mesmo e copolìmero de siloxano de cadeia lateral fluorada
ATE4115T1 (de) 6-substituierte 11-alkylen-morphantridine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
PL378076A1 (pl) Transdermalny system terapeutyczny nadający się do użycia ciepła w celu przyspieszenia przenikania substancji czynnych i jego zastosowanie
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
NO20001812L (no) Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav
AU701327B2 (en) Preperation for the prophylaxis and/or treatment of wool and hair loss
DE60013636D1 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
DE69432517D1 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
DE69813247D1 (de) Verbindungen zur verwendung in der krebsbehandlung
CO4970785A1 (es) Composiciones y metodos para tratar con metilfenidato el deficit de la atencion y el deficit de la atencion con hiperactividad
DK0946621T3 (da) Kationiske filmdannende polymersammensætninger indeholdende samme og anvendelser deraf, herunder topisk afleveringssystem og fremgangsmåde til aflevering af midler til huden og håret